Fragment 176-191, a modified AOD 9604 peptide, is a growth hormone (hGH) fragment. The 176th to the 191st aminos are separated from the chain, with one more amino acid (Tyrosine) added to the fragment. This growth hormone peptide (hGH) fragment has been speculated by researchers to potentiate lipolysis, or fat cell decomposition, a role initially linked to hGH for the first time in the late 1950s.

hGH fragment 176-191 is frequently considered an imitation of hGH’s C-terminal. The synthetic peptide contains the last 16 aminos in the hormone’s sequence. This hGH area has been associated with reduced fatty tissue from widespread animal model studies through the proposed slowing of lipogenesis and stimulation of lipolysis.(1) This fragment, however, has also been linked to insulin restriction and has, therefore, been considered a catalyst for the risks of hyperglycemia.

This impact may be associated with amino acids 176 to 191 in the sequence of growth hormone. Contrarily, the hGH amino-terminus has presented a possibly major impact on the breakdown of glucose, arbitrated by insulin in control rodents. Studies on animals exploring the hGH fragment properties have suggested that the fragment may disturb glycogen synthase management, which may induce changes in circulating glucose levels.

With the addition of amino acid 176, the fragment becomes a growth-hormone releasing factor (GRF) analog. This peptide, then, is classified as a growth hormone releasing hormone, and may potentially function partly as a growth hormone release regulator as well. Growth hormone doesn’t typically exhibit an adverse impact on insulin’s effects, suggested, therefore, that the breakdown of glucose may potentially be boosted by the protein sequence’s opposite end.(2)

Research in hGH’s 176-191 peptide fragment has linked the peptide to possible changes in glycogen synthase phosphatase inactivation in the muscle tissue of rodents, which may then alter within cells the active glycogen synthase concentration. That’s why shortened versions of growth hormone, such as the hGH fragment, may potentially disturb the normal metabolism of glycogen or glucose.


Fragment 176-191 Peptide Research

Researchers suggest Fragment 176-191 peptide may exhibit potential in fat cell consumption. Research has indicated that the peptide fragment may provide significant, impactful changes as compared to its endogenous version. Findings in laboratory research suggest that Fragment 176-191 peptide may potentially encourage fat cell breakdown, similar to the way growth hormone is considered to impact such tissues, and may potentially inhibit the conversion of fatty foods into fat cells.

Growth hormone releasing factor has been suggested to impact, and likely elevate growth hormone plasma levels. Scientists have posited that long-term exposure to growth hormone releasing factor may have induced a major rise in progesterone and luteinizing hormone (LH) concentrations in animal models. Growth hormone releasing factor may also be linked to dyslipidemia decrease. Dyslipidemia is the impairment of fat metabolism which then causes fat cells to accumulate at greater rates. Due to this assumption on the impact on dyslipidemia, researchers suggest that analogs of GRF might be similarly positioned to improve body composition and reduce total fat cell storage in animal research models.

The releasing factor of growth hormone, as well as its analogs, have been considered by scientists to encourage the release of growth hormone from tissues like the pituitary gland, which is why they might also impact progesterone concentrations and various other hormones. Additionally, analogs of GRF may exhibit more stability than full growth hormone proteins themselves.

Fragment 176-191 peptide might be used to explore the presumed functions of either growth hormone or GRF in senescence or other age-related processes, as well as the response to altered feeding patterns of non-human subjects. The peptide fragment may also be researched to better understand the managerial axis of GRF, IGF and growth hormone.

GRF might exhibit a function in pre- and postnatal organism development. As GRF is one of a large family of peptide hormones & similar molecules, an analog of GRF that is both bioactive and stable may potentially make for a interesting testing candidate for further research. Growth hormone releasing factor, along with its analogs, have been linked to both growth hormone, and, potentially, IGF release. GRF release has, for a long time, been linked to the hypothalamus, though it has been reported in other areas as well. It is due in part to the possibility that GRF may be isolated in areas like the gonads and the placenta that scientists suggest the peptide may play a part in fetal development. GRF is also found in leukocytes, which is why it has been considered for research within the context of immune management or the immune response.


Fragment 176-191 Peptide and Weight

Studies in rodents that have undergone long-term Fragment 176-191 peptide exposure have proposed that it may potentially activate metabolic processes to induce overall body weight loss. While researchers don’t exactly know why this is, they consider it probable that lipolysis may occur when the peptide sticks to the ß3-A receptors, which are associated with fat burn. Studies have suggested a causal relationship between hGH peptide fragment and decreased fat tissue storage in rodents, though it isn’t linked to the disintegration of current fat stores. The 16 amino acid chain fragment, in its entirety, appears to imitate the GRF. Analogs of GRF or GH might be linked to decreased fat deposits in animals who are exposed to this chemical.(3)

Additional research has suggested this fragment’s potential to raise IGF-1 levels, which has been linked to other physical impacts including typically “anti-aging” consequences, such as the supplementation of certain proteins whose natural production is inclined to taper upon organism maturity. These impacts have also included potential changes in sleep cycle patterns and possible increases in bone mineral density of research models.

If you are a lab researcher looking to purchase top grade peptides for sale from a reputable source, you can buy Fragment 176-191 by visiting Core Peptides. The peptides available commercially including those available for sale here are strictly for research and laboratory use, and are not approved for personal use or human consumption.

NOTE: These products are intended for laboratory research use only. This peptide is not intended for personal use. Please review and adhere to our Terms and Conditions before ordering.


  1. Wu Z., et al. Antilipogenic action of synthetic C-terminal sequence 176 191 of hgh. Biochemistry and molecular biology international, 1993.
  2. Mondon C. E., et al. Amino-terminal peptide of gh enhances insulin action in normal rats. Endocrinology, 1988.
  3. Mangili A., et al. Predictors of Treatment Response to Tesamorelin, a GRF Analog, in HIV-Infected Patients with Excess Abdominal Fat, 2015.
    Your Cart
    Your cart is empty